Objectives: The aim of this study will investigate impact of curcumin capsules on serum levels of pro-inflammatory/anti-inflammatory cytokines and adhesion molecules in Non-alcoholic fatty liver disease (NAFLD).
Design: This randomized (by using random numbers table), double-blinded, placebo- controlled clinical trial in 80 NAFLD patients.
Setting and conduct: patients with inclusion criteria: for participation of patients in the study will be diagnosed with MetS according to the Adult Treatment Panel (ATP) III criteria also inclusion criteria were diagnosis of NAFLD (grades 1– 3) according to liver ultrasonography.
Exclusion criteria were pregnancy or breastfeeding, NAFLD secondary to alcohol consumption, smoking, consumption of hypoglycemic, hypolipidemic, and anti-inflammatory medications as well as any drug known to affect hepatic function, and the presence of hepatitis, coronary, renal, pulmonary, and thyroid diseases.
Eligible subjects will be randomly divided into two treatment groups and control.
Interventions: In the treatment group take curcumin (500 mg/day of an amorphous dispersion preparation comprising 70-mg curcuminoids) (n = 40) or placebo (n = 40).
The main outcome variables: At the beginning and end of a month of blood samples for determination of pro-inflammatory/anti-inflammatorycytokines(IL-6, IL-8, TNF-α, IL-1, VEGF, IL-10, MCP-1, MCP-1) and adhesion molecules(L-selectin, P-selectin, E-selectin, ICAM-1 and VCAM-1).